Literature DB >> 4402069

Cyclic adenosine monophosphate phosphodiesterase in brain: effect on anxiety.

B Beer, M Chasin, D E Clody, J R Vogel.   

Abstract

Drugs that reduce anxiety may be mediated by cyclic adenosine monophosphate in the brain because (i) potent anxiety-reducing drugs are also potent inhibitors of brain phosphodiesterase activity; (ii) dibutyryl cyclic adenosine monophosphate has the ability to reduce anxiety; (iii) the methylxanthines show significant anxiety-reducing effects; (iv) theophylline and chlordiazepoxide produce additive anxiety-reducing activity; and (v) there is a significant correlation between the anxiety-reducing property of drugs and their ability to inhibit phosphodiesterase activity in the brain.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4402069     DOI: 10.1126/science.176.4033.428

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  29 in total

1.  Effects of acute and chronic interactions of diazepam and d-amphetamine on punished behavior of rats.

Authors:  R D Ford; R H Rech; R L Commissaris; L Y Meyer
Journal:  Psychopharmacology (Berl)       Date:  1979-10       Impact factor: 4.530

2.  Effect of some phosphodiesterase inhibitors on two different preparations of adenosine 3',5'-monophosphate phosphodiesterase.

Authors:  A Du Moulin; J Schultz
Journal:  Experientia       Date:  1975-08-15

3.  Single-dose tolerance to the behavioral effects of dibutyryl cyclic AMP in mice.

Authors:  M Weiner; J W Olson
Journal:  Psychopharmacology (Berl)       Date:  1977-08-31       Impact factor: 4.530

4.  Diethylstilbestrol potentiation of the dopamine-elicited formation of adenosine 3',5'-monophosphate in incubated male rat hypothalamus.

Authors:  B A Weissman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-05       Impact factor: 3.000

5.  Effects of arecoline and cholinesterase inhibitors on cyclic guanosine 3',5'-monophosphate and adenosine 3'.5'-monophosphate in mouse brain.

Authors:  V Dinnendahl; K Stock
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1975       Impact factor: 3.000

6.  Benzodiazepines and central inhibitory mechanisms.

Authors:  H M Geller; D A Taylor; B J Hoffer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-09       Impact factor: 3.000

7.  Unspecific and specific stimulating effects of 3',5'-cyclic nucleotides (cGMP, cAMP, cIMP, cCMP) on the in vitro biosynthesis of proteochondroitin-4,-6-sulfate and on other anabolic processes from calf rib cartilage.

Authors:  T O Kleine; K Schippers
Journal:  Agents Actions       Date:  1978-12

8.  Effects of tetrahydrocannabinols on cyclic AMP levels in rat brain areas.

Authors:  W E Askew; B T Ho
Journal:  Experientia       Date:  1974-08-15

Review 9.  Social stress, therapeutics and drug abuse: preclinical models of escalated and depressed intake.

Authors:  Klaus A Miczek; Jasmine J Yap; Herbert E Covington
Journal:  Pharmacol Ther       Date:  2008-08-15       Impact factor: 12.310

10.  Alprazolam, caffeine and their interaction: relating DRL performance to pharmacokinetics.

Authors:  C E Lau; J Wang
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.